Hepatocellular Carcinoma New Reference: Cabozantinib and Atezolizumab in HCC Ulas D. Bayraktar, MD 2022-11-26
Hodgkin Lymphoma New Reference: Bretuximab Vedotin in Stage III-IV Hdogkin Lymphoma Ulas D. Bayraktar, MD 2022-11-26
Breast Cancer New Protocol: Pembrolizumab with Chemotherapy in Triple-Negative Breast Cancer Ulas D. Bayraktar, MD 2022-11-26
Renal Cell Carcinoma New Reference: Nivolumab and Cabozantinib for Advanced RCC Ulas D. Bayraktar, MD 2022-09-20
Nervous System Tumor Thyroid Cancer New Indication: Dabrafenib and Trametinib in bRAV V600E Mutant Anaplastic Thyroid Cancer Ulas D. Bayraktar, MD 2022-09-20
Gastrointestinal Stromal Tumor New Drug: Ripretinib for Advanced GIST Ulas D. Bayraktar, MD 2022-09-20
Non-Small Cell Lung Cancer New Indication: Neoadjuvant Nivolumab for NSCLC Ulas D. Bayraktar, MD 2022-09-20
Mantle cell lymphoma New Protocol: Ibrutinib with Rituximab and Bendamustine for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2022-09-20
